307 related articles for article (PubMed ID: 31931812)
41. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies.
Pietsch EC; Dong J; Cardoso R; Zhang X; Chin D; Hawkins R; Dinh T; Zhou M; Strake B; Feng PH; Rocca M; Santos CD; Shan X; Danet-Desnoyers G; Shi F; Kaiser E; Millar HJ; Fenton S; Swanson R; Nemeth JA; Attar RM
Blood Cancer J; 2017 Feb; 7(2):e536. PubMed ID: 28234345
[TBL] [Abstract][Full Text] [Related]
42. A Novel Anti-CD47 Nanobody Tetramer for Cancer Therapy.
Ratnikova NM; Kravchenko Y; Ivanova A; Zhuchkov V; Frolova E; Chumakov S
Antibodies (Basel); 2024 Jan; 13(1):. PubMed ID: 38247566
[TBL] [Abstract][Full Text] [Related]
43. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
[TBL] [Abstract][Full Text] [Related]
44. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
Zhang J; Jin S; Guo X; Qian W
J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
[TBL] [Abstract][Full Text] [Related]
45. Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRPα "don't eat me" immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation.
Hendriks MAJM; Ploeg EM; Koopmans I; Britsch I; Ke X; Samplonius DF; Helfrich W
Oncoimmunology; 2020 Sep; 9(1):1824323. PubMed ID: 33299654
[TBL] [Abstract][Full Text] [Related]
46. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.
Chao MP; Tang C; Pachynski RK; Chin R; Majeti R; Weissman IL
Blood; 2011 Nov; 118(18):4890-901. PubMed ID: 21828138
[TBL] [Abstract][Full Text] [Related]
47. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
48. Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy.
Yang Y; Yang Z; Yang Y
Front Immunol; 2021; 12():686031. PubMed ID: 34305918
[TBL] [Abstract][Full Text] [Related]
49. High-affinity decoy protein, nFD164, with an inactive Fc region as a potential therapeutic drug targeting CD47.
Wang Z; Hu N; Wang H; Wu Y; Quan G; Wu Y; Li X; Feng J; Luo L
Biomed Pharmacother; 2023 Jun; 162():114618. PubMed ID: 37011485
[TBL] [Abstract][Full Text] [Related]
50. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
Buatois V; Johnson Z; Salgado-Pires S; Papaioannou A; Hatterer E; Chauchet X; Richard F; Barba L; Daubeuf B; Cons L; Broyer L; D'Asaro M; Matthes T; LeGallou S; Fest T; Tarte K; Clarke Hinojosa RK; Genescà Ferrer E; Ribera JM; Dey A; Bailey K; Fielding AK; Eissenberg L; Ritchey J; Rettig M; DiPersio JF; Kosco-Vilbois MH; Masternak K; Fischer N; Shang L; Ferlin WG
Mol Cancer Ther; 2018 Aug; 17(8):1739-1751. PubMed ID: 29743205
[TBL] [Abstract][Full Text] [Related]
51. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer.
Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
[TBL] [Abstract][Full Text] [Related]
52. Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice.
Li Y; Zhang M; Wang X; Liu W; Wang H; Yang YG
Nat Commun; 2020 Jan; 11(1):581. PubMed ID: 31996683
[TBL] [Abstract][Full Text] [Related]
53. A Novel Affinity Engineered Anti-CD47 Antibody With Improved Therapeutic Index That Preserves Erythrocytes and Normal Immune Cells.
Thaker YR; Rivera I; Pedros C; Singh AR; Rivero-Nava L; Zhou H; Swanson BA; Kerwin L; Zhang Y; Gray JD; Kaufmann GF; Ji H; Allen RD; Bresson D
Front Oncol; 2022; 12():884196. PubMed ID: 35664753
[TBL] [Abstract][Full Text] [Related]
54. Durable antitumor responses to CD47 blockade require adaptive immune stimulation.
Sockolosky JT; Dougan M; Ingram JR; Ho CC; Kauke MJ; Almo SC; Ploegh HL; Garcia KC
Proc Natl Acad Sci U S A; 2016 May; 113(19):E2646-54. PubMed ID: 27091975
[TBL] [Abstract][Full Text] [Related]
55. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
[TBL] [Abstract][Full Text] [Related]
56. Monoclonal anti-CD47 interference in red cell and platelet testing.
Velliquette RW; Aeschlimann J; Kirkegaard J; Shakarian G; Lomas-Francis C; Westhoff CM
Transfusion; 2019 Feb; 59(2):730-737. PubMed ID: 30516833
[TBL] [Abstract][Full Text] [Related]
57. CD20-selective inhibition of CD47-SIRPα "don't eat me" signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.
van Bommel PE; He Y; Schepel I; Hendriks MAJM; Wiersma VR; van Ginkel RJ; van Meerten T; Ammatuna E; Huls G; Samplonius DF; Helfrich W; Bremer E
Oncoimmunology; 2018; 7(2):e1386361. PubMed ID: 29308308
[TBL] [Abstract][Full Text] [Related]
58. Advances in the study of CD47-based bispecific antibody in cancer immunotherapy.
Zhang B; Li W; Fan D; Tian W; Zhou J; Ji Z; Song Y
Immunology; 2022 Sep; 167(1):15-27. PubMed ID: 35575882
[TBL] [Abstract][Full Text] [Related]
59. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors.
Gholamin S; Mitra SS; Feroze AH; Liu J; Kahn SA; Zhang M; Esparza R; Richard C; Ramaswamy V; Remke M; Volkmer AK; Willingham S; Ponnuswami A; McCarty A; Lovelace P; Storm TA; Schubert S; Hutter G; Narayanan C; Chu P; Raabe EH; Harsh G; Taylor MD; Monje M; Cho YJ; Majeti R; Volkmer JP; Fisher PG; Grant G; Steinberg GK; Vogel H; Edwards M; Weissman IL; Cheshier SH
Sci Transl Med; 2017 Mar; 9(381):. PubMed ID: 28298418
[TBL] [Abstract][Full Text] [Related]
60. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors.
Liu X; Pu Y; Cron K; Deng L; Kline J; Frazier WA; Xu H; Peng H; Fu YX; Xu MM
Nat Med; 2015 Oct; 21(10):1209-15. PubMed ID: 26322579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]